Comparative study on reference change values and reference change factors of tumor markers

doi:10.3969/j.issn.1673-8640.2019.11.007

Abstract

Abstract:

Objective To calculate the reference change values（RCV） and reference change factors（RCF） of 7 tumor markers [alpha-fetoprotein（AFP）,carcinoembryonic antigen（CEA）,carbohydrate antigen（CA）125,CA15-3,CA19-9,free prostate-specific antigen（f-PSA） and total prostate-specific antigen （t-PSA）]. Methods The unidirectional ranges and bidirectional ranges of RCV and RCF reference change upper limit factor（RCF_up） and reference change lower limit factor（RCF_down） were calculated. Results The RCV and RCF of AFP,CEA,CA125,CA15-3,CA19-9,f-PSA and t-PSA were calculated according to the formulas. Conclusions It is recommended that clinical laboratories use both RCV and RCF as reference intervals for healthy subjects. RCF is used as a method for clinical dynamic interpretation when continuously monitoring related indicators of tumor patients.

Key words: Reference change value, Reference change factor, Tumor marker, Biological variation

CLC Number:

R446.1

ZHANG Li, HE Yao. Comparative study on reference change values and reference change factors of tumor markers[J]. Laboratory Medicine, 2019, 34(11): 991-993.

项目	CV_I	CV_A	RCV（P<0.05）		RCV（P<0.01）
项目	CV_I	CV_A	单向	双向	单向	双向
AFP	12.0	4.45	29.86	35.48	42.17	46.70
CEA	12.7	2.78	30.33	36.03	42.84	47.43
CA125	24.7	11.67	63.75	75.73	90.02	99.68
CA15-3	6.1	2.35	15.26	18.13	21.55	23.86
CA19-9	16.0	6.35	40.16	47.70	56.71	62.79
f-PSA	18.1	3.12	42.86	50.91	60.52	67.01
t-PSA	18.1	3.13	42.87	50.92	60.53	67.03

项目	CV_I	CV_A	RCV（P<0.05）		RCV（P<0.01）
项目	CV_I	CV_A	单向	双向	单向	双向
AFP	12.0	4.45	29.86	35.48	42.17	46.70
CEA	12.7	2.78	30.33	36.03	42.84	47.43
CA125	24.7	11.67	63.75	75.73	90.02	99.68
CA15-3	6.1	2.35	15.26	18.13	21.55	23.86
CA19-9	16.0	6.35	40.16	47.70	56.71	62.79
f-PSA	18.1	3.12	42.86	50.91	60.52	67.01
t-PSA	18.1	3.13	42.87	50.92	60.53	67.03

项目	CV_I（%）	CV_A（%）	RCF
			单向（P<0.05）		双向（P<0.05）		单向（P<0.01）		双向（P<0.01）
			RCF_up	RCF_down	RCF_up	RCF_down	RCF_up	RCF_down	RCF_up	RCF_down
AFP	12.0	4.45	1.35	0.74	1.43	0.70	1.52	0.66	1.60	0.63
CEA	12.7	2.78	1.35	0.74	1.43	0.70	1.53	0.65	1.61	0.62
CA125	24.7	11.67	1.89	0.53	2.13	0.47	2.46	0.41	2.71	0.37
CA15-3	6.1	2.35	1.16	0.86	1.20	0.83	1.24	0.81	1.27	0.79
CA19-9	16.0	6.35	1.49	0.67	1.61	0.62	1.76	0.57	1.87	0.53
f-PSA	18.1	3.12	1.54	0.65	1.66	0.60	1.83	0.55	1.95	0.51
t-PSA	18.1	3.13	1.54	0.65	1.66	0.60	1.83	0.55	1.95	0.51

项目	CV_I（%）	CV_A（%）	RCF
			单向（P<0.05）		双向（P<0.05）		单向（P<0.01）		双向（P<0.01）
			RCF_up	RCF_down	RCF_up	RCF_down	RCF_up	RCF_down	RCF_up	RCF_down
AFP	12.0	4.45	1.35	0.74	1.43	0.70	1.52	0.66	1.60	0.63
CEA	12.7	2.78	1.35	0.74	1.43	0.70	1.53	0.65	1.61	0.62
CA125	24.7	11.67	1.89	0.53	2.13	0.47	2.46	0.41	2.71	0.37
CA15-3	6.1	2.35	1.16	0.86	1.20	0.83	1.24	0.81	1.27	0.79
CA19-9	16.0	6.35	1.49	0.67	1.61	0.62	1.76	0.57	1.87	0.53
f-PSA	18.1	3.12	1.54	0.65	1.66	0.60	1.83	0.55	1.95	0.51
t-PSA	18.1	3.13	1.54	0.65	1.66	0.60	1.83	0.55	1.95	0.51

[1]	DITTADI R,FIORIN DAMIANI A,OLCESE C.Evaluation of serum cortisol biological variation in the evening withdrawal[J]. Clin Chem Lab Med,2017,55(12):e285-e287.
[2]	FRASER C G.Inherent biological variation and reference values[J]. Clin Chem Lab Med,2004,42(7):758-764.
[3]	COSKUN A,SERTESER M,KARPUZOGLU H F,et al.How can we evaluate differences between serial measurements on the same sample? A new approach based on within-subject biological variation[J]. Clin Chem Lab Med,2017,55(2): e44-e46.
[4]	PETERSEN P H, FRASER C G.Strategies to set global analytical quality specifications in laboratory medicine:10 years on from the Stockholm consensus conference[J]. Accred Qual Assur,2010,15:323-330.
[5]	BUGDAYCI G,OGUZMAN H,ARATTAN H Y,et al.The use of reference change values in clinical laboratories[J]. Clin Lab,2015,61:251-257.
[6]	RICÓS C,IGLESIAS N,GARCÍA-LARIO J,et al. Within-subject biological variation in disease:collated data and clinical consequences[J]. Ann Clin Biochem,2007,44:343-352.

Comparative study on reference change values and reference change factors of tumor markers

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 6

Related Articles 15

Recommended Articles

Metrics

[1]	WANG Wei, ZHANG Zhixin, ZHANG Chuanbao, ZHOU Weiyan, WANG Zhiguo. Establishment of allowable total error，allowable imprecision and allowable bias for 22 endocrine analytes [J]. Laboratory Medicine, 2023, 38(8): 707-712.
[2]	GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine：from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312.
[3]	XU Runhao, ZOU Chen, CAO Yun, CHEN Feng, LIU Yijing, ZHANG Shulin, ZHANG Jie. Roles of serum amino acid determinations in the diagnosis of early non-small-cell lung cancer [J]. Laboratory Medicine, 2022, 37(12): 1157-1163.
[4]	XIONG Zhongbo, WANG Lei, YIN Beiqi, DAI Yue, WEI Xiaoqing, LU Pei. Clinical roles of SAA and CRP in pathological staging and metastasis of gastrointestinal cancer [J]. Laboratory Medicine, 2022, 37(1): 51-55.
[5]	MAN Xianfeng, HE Xiaoting, ZHANG Ying, YU Weiwei, WANG Qi, YIN Hanwei, WANG Runjie. Application of thioredoxin reductase in monitoring the curative effect of lung cancer [J]. Laboratory Medicine, 2022, 37(1): 56-59.
[6]	YUE Bo, LI Danjie, TANG Dahai, LIU Manjiao, HE Jialei, JIANG Mengjie, WEI Xiaoqiang. Establishment of a new algorithm for the reference interval of relative change values and application evaluation [J]. Laboratory Medicine, 2021, 36(6): 667-673.
[7]	MIAO Yingbo, SONG Ying, ZHAO Qiang, ZHU Peichao, ZHOU Wei, WANG Qing, XU Chong. Performance specification for differential blood count project in Shanghai [J]. Laboratory Medicine, 2021, 36(12): 1274-1276.
[8]	XU Runhao, ZOU Chen, ZHANG Jie, LI Min, ZHANG Shulin. Application of serum bile acid spectrum in the differential diagnosis of pneumonia and lung cancer [J]. Laboratory Medicine, 2021, 36(1): 1-7.
[9]	LIU Wenbin, JU Yi, TANG Liping, WANG Meijuan, OU Yuanzhu, YU Xiaoxuan, LI Qing. IFCC Secondary Reference Measurement Procedure for 4 HbA_1c determination systems [J]. Laboratory Medicine, 2019, 34(5): 443-446.
[10]	GAO Feng. Research improvement of the basis and transformation of tumor markers in clinical laboratories [J]. Laboratory Medicine, 2019, 34(2): 95-97.
[11]	LIU Xia, WU Yanyan, WANG Jinling, LAN He, LIU Li, WANG Peichang. Tumor diagnostic rate and tumor marker determination for 84 patients with typical paraneoplastic antibody positive [J]. Laboratory Medicine, 2018, 33(8): 702-706.
[12]	ZHANG Haichen, WANG Hao, SONG Yunxiao, MA Jin. Combined determination of multiple tumor markers for the diagnosis of primary lung cancer [J]. Laboratory Medicine, 2018, 33(7): 590-596.
[13]	WU Yongchun. Tumor markers for the combined screening of female genital tract cancer and breast cancer [J]. Laboratory Medicine, 2018, 33(6): 512-515.
[14]	DU Yan, LIU Hua, ZHANG Boke, LIU Yiwen, HE Yiqing, YANG Cuixia, ZHANG Guoliang, GAO Feng. Peripheral blood monocyte M2/M1 ratio for the diagnosis of breast cancer [J]. Laboratory Medicine, 2018, 33(5): 421-424.
[15]	WANG Qi, WANG Baolong. Research progress of exosomes in tumor diagnosis [J]. Laboratory Medicine, 2018, 33(12): 1148-1152.